Plug-and-play antibodies and vaccines for emerging RNA viruses
Official title: PROVIDENT: Prepositioning Optimized Strategies for Vaccines and Immunotherapeutics against Diverse Emerging Infectious Threats
Funded at Albert Einstein College of Medicine · NIH-11565889 · Data updated 2026-11-12
A nationwide team is building ready-to-use vaccine and antibody blueprints to rapidly respond to emerging RNA viruses in three families.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project start | September 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $40,824 |
| NIH project number | 3U19AI181977-03S1 |
| Project ID | NIH-11565889 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are populations at risk from emerging enveloped RNA viruses and those who may later participate in clinical testing of accelerated vaccine or antibody programs.
✕Less likely to help
Early-stage research and platform development may not immediately benefit any individual patient.
What this research studies
This program brings together academic, government, and industry partners to create modular vaccine and antibody designs that can be manufactured quickly and meet regulatory needs. Researchers will identify host factors, engineer antigens, and test RNA vaccine platforms to optimize immune responses and safety. The project is organized into multiple research projects, cores for data management, and administrative oversight to accelerate development. An initial prototype virus strategy will guide discovery and enable rapid adaptation to new threats.
Why it matters
Potential benefit: If successful, patients could benefit from faster availability of effective vaccines and antibody therapies against emerging viral threats.
How similar studies have gone: Prior modular vaccine/antibody platforms have shown promise in accelerating development for influenza and other viruses, with ongoing demonstrations of rapid design and testing.
Where this research is happening
-
Albert Einstein College of Medicine
Bronx, United States Active
Researchers
- Principal investigator: Chandran, Kartik — Albert Einstein College of Medicine
- Study coordinator: Chandran, Kartik
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.